• Cart$0
    • No products in the cart.
Personalize Medicine. Save Lives. close

The New Gold Standard in Epigenetic Diagnostic Tests
Leading the way in DNA Methylation Diagnostic and Research Solutions

  • Making more of specific proteins helps cancer cells survive under conditions which would kill normal cells. All these cells are being starved. The large cells have been genetically modified to over-express SMAC/DIABLO (green), one protein involved in apoptosis. The normal cells are stressed and form red stress granules. Understanding how cancer cells subvert the death pathway may lead to new ways to treat cancer. Immunofluorescent photomicrograph. --- Image by © Nancy Kedersha/Science Faction/Corbis

Research Products & Services

RiboMed provides a variety of versitle bisulfite-free research tools and services for the study of CpG methlation in DNA.

•  MethylMeter®: Quantitative DNA Methylation Detection

•  MethylMagnet®: Ultra Sensitive Methylated DNA isolation

•  CAP: Pioneering  ”Coupled Abscription PCR ” DNA Methylation Detection

read more

Clinical Diagnostics

RiboMed’s proprietary Abscription®-based DNA methylation diagnostic tests are leading the way in epigenetic and cancer diagnostics.

• Proprietary bisulfite free DNA Methylation Detection Clinical Diagnostic Assay Platform

• Prognostic Brain Tumor FFPE Assay Now Available Through Castle Biosciences

• Theranostic Ovarian Cancer Assay (Q4 2012)

read more                 order test

Latest News

• April 2012 – RiboMed Launches Prognostic Test  for Glioma Brain Cancer

RiboMed Receives Notice of Allowance for Three New Patents  (a)  Detecting CpG Methylation With a Methyl CpG Binding Protein (b) Molecular Beacon Abscription Detection (c) Abscription-Based Molecular Detection 

read more

© Copyright 2012. RiboMed Biotechnologies Inc. All rights reserved. - Ribomed -